Filing Details

Accession Number:
0001214659-18-001631
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-27 18:00:14
Reporting Period:
2018-02-23
Accepted Time:
2018-02-27 18:00:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX Pharmaceutical Preparations (2834) 462693615
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1579824 M Charles Baum C/o Mirati Therapeutics Inc.
9393 Towne Centre Drive, Ste 200
San Diego CA 92121
President & Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-02-23 51,810 $8.50 100,366 No 4 M Direct
Common Stock Disposition 2018-02-23 40,748 $27.89 59,618 No 4 S Direct
Common Stock Disposition 2018-02-23 11,062 $28.56 50,932 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Disposition 2018-02-23 51,810 $0.00 51,810 $8.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
155,430 2020-07-16 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
  2. This transaction was executed in multiple trades at prices ranging from $27.45 to $28.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $28.45 to $28.725. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. 20% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020.
  5. Includes 2,376 shares acquired under the ESPP Purchase on 11/30/17.